NeoGenomics's (NASDAQ:NEO) Q1 CY2026: Beats On Revenue [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
The company expects the full year's revenue to be around $800 million, close to analysts' estimates. Its non-GAAP profit of $0.01 per share was in line with analysts' consensus estimates. Is now the time to buy NeoGenomics? Find out in our full research report NeoGenomics (NEO) Q1 CY2026 Highlights: Revenue: $186.7 million vs analyst estimates of $184.5 million (11.1% year-on-year growth, 1.2% beat) Adjusted EPS: $0.01 vs analyst estimates of $0 (in line) Adjusted EBITDA: $9.00 million vs analyst estimates of $8.33 million (4.8% margin, 8% beat) The company slightly lifted its revenue guidance for the full year to $800 million at the midpoint from $797 million EBITDA guidance for the full year is $56 million at the midpoint, in line with analyst expectations Operating Margin: -9.8%, up from -16.6% in the same quarter last year Free Cash Flow was -$13.14 million compared to -$29.83 million in the same quarter last year Market Capitalization: $1.12 billion “The fir
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- Wall Street's Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets [TheStreet.com]TheStreet.com
- NeoGenomics (NEO) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $25.00 price target on the stock.MarketBeat
- NeoGenomics (NEO) was upgraded by Benchmark Co. from "hold" to "buy".MarketBeat
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 4/28/26 - Beat
NEO
Sec Filings
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- 4/6/26 - Form DEFA14A
- NEO's page on the SEC website